BARCELONA, Feb 28 Reuters Spanish pharmaceuticals company Grifols39; fullyear net profit rose 10 to 208 million euros 220.19 million as blood plasma collection grew more than 25 and said it expects core earnings to grow significantly in 2023.

Grifols, which uses blood plasma to make medicines, reported on Tuesday total revenues of 6 billion euros, a 23 hike from 2021, with over half generated in the United States and Canada. Its earnings before interest, taxes, depreciation, and amortisation EBITDA rose 27 yearonyear to 1.2 billion euros.

The reported net profit was below Refinitiv39;s estimate of 280 million euros, revenue was slightly above, while its EBITDA was in line with estimates.

The Barcelonabased company, which was severely hit at the start of the pandemic due to plasma shortages, expects its EBITDA to rise to 1.7 billion euros in 2023 while its total revenue is forecast to rise 810, which would be a lower rate than in 2022.

Grifols said it achieved its 2022 targets.

For 2023, we believe the company has a solid base upon which to build its future, its two coChief Executives Victor Grifols and Raimon Grifols said in a statement, noting the company had to take difficult but necessary measures.

Grifols announced earlier this month it would lay off around 2,300 employees, or 8.5 of its global workforce, amid a strategy overhaul aimed at reaching annual savings of around 400 million euros.

A week after the announcement, it said Steven F. Mayer had resigned…